3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
5
Phase 3
2
Phase 1/2
2
Phase 1
1
Status
Active not recruiting
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Gastrointestinal
2
Conditions
Carcinoma, Hepatocellular
5
Urinary Bladder Neoplasms
2
Small Cell Lung Carcinoma
2
Liver Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Urothelial Cancer
1
Squamous Cell Carcinoma of Head and Neck
1
Recurrence
1
Non Small Cell Lung Cancer NSCLC
1
Non - Small Cell Lung Cancer NSCLC
1
Melanoma
1
Lung Neoplasms
1
Head and Neck Neoplasms
1
Diabetes Mellitus, Insulin-Dependent, 12
1
Carcinoma, Renal Cell
1
Carcinoma
1
Interventions
Sorafenib
8
durvalumab
4
Cisplatin
4
Gemcitabine
3
Ethiodized Oil
3
Doxorubicin
3
Chemotherapy, Adjuvant
3
Bevacizumab
3
tremelimumab
2
sodium thiosulfate
2
phosphomannopentaose sulfate
2
Watchful Waiting
2
Talaporfin
2
Radiofrequency Ablation
2
Oxaliplatin
2
Nivolumab
2
Folfox protocol
2
Celecoxib
2
Capecitabine
2
Analgesia, Patient-Controlled
2
seocalcitol
1
parecoxib
1
nolatrexed
1
linifanib
1
lenvatinib
1
ferumoxides
1
ferric carboxymaltose
1
contrast agent BR1
1
cabozantinib
1
brivanib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 3
×
Liver Neoplasms
×
tremelimumab
×
Clear all
NCT05883644
2026-04-30
SIERRA
AstraZeneca
Phase 3
Active not recruiting
111 enrolled
NCT05301842
2026-04-07
EMERALD-3
AstraZeneca
Phase 3
Active not recruiting
760 enrolled